SPECIALTY GUIDELINE MANAGEMENT

EXONDYS 51 (eteplirsen)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Exondys 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with Exondys 51. A clinical benefit of Exondys 51 has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

A. Initial requests: laboratory confirmation of Duchenne muscular dystrophy (DMD) diagnosis with a DMD gene mutation that is amenable to exon 51 skipping (refer to examples in Appendix)

B. Continuation of therapy requests: documentation (e.g., chart notes) of response to therapy

III. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a physician who specializes in treatment of DMD.

IV. CRITERIA FOR INITIAL APPROVAL

Duchenne Muscular Dystrophy

Authorization of 6 months may be granted for treatment of DMD when all of the following criteria are met:

A. Genetic testing was conducted to confirm the diagnosis of DMD and to identify the specific type of DMD gene mutation.

B. The DMD gene mutation is amenable to exon 51 skipping (refer to examples in Appendix).

C. Treatment with Exondys 51 is initiated before the age of 14.

D. Member is able to achieve an average distance of at least 180 meters while walking independently over 6 minutes.

E. Member will not exceed a dose of 30 mg/kg.
V. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for members requesting continuation of therapy when both of the following criteria are met:
A. The member has demonstrated a response to therapy as evidenced by remaining ambulatory (e.g., able to walk with or without assistance, not wheelchair dependent).
B. The member will not exceed a dose of 30 mg/kg.

VI. APPENDIX

Examples of DMD gene mutations (exon deletions) amenable to exon 51 skipping
1. Deletion of exon 50
2. Deletion of exon 52
3. Deletion of exons 45-50
4. Deletion of exons 47-50
5. Deletion of exons 48-50
6. Deletion of exons 49-50

VII. REFERENCES